PF 6412562

Drug Profile

PF 6412562

Alternative Names: PF-06412562; PF-6412562

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cognition disorders; Parkinson's disease; Schizophrenia

Most Recent Events

  • 08 May 2017 University of Zurich initiates enrolment in a phase I trial in Healthy volunteers in Switzerland (NCT03181841)
  • 01 Nov 2016 Discontinued - Phase-I for Cognition disorders (In volunteers) in Belgium, Sweden (PO) (Pfizer pipeline, February 2017)
  • 01 Nov 2016 Discontinued - Phase-I for Cognition disorders (In volunteers) in USA (PO) (Pfizer pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top